Market Research Logo

Global Kidney Cancer Drugs Market 2015-2019

Global Kidney Cancer Drugs Market 2015-2019

About Kidney Cancer

Kidney cancer also known as renal cancer affects the kidney cells. RCC is the most common form of kidney cancer in adults and Wilms' tumor in children. The exact cause of the disease is not yet known. The symptoms of renal cancer are often confused with other kidney disorders. This usually results in late stage detection of the disease, which leads to less chances of patient survival. In the majority of cases, it is diagnosed accidentally, when the patient undergoes checkups for other disorders.Kidney cancer can be triggered by a number of factors including both lifestyle-related changes and genetic changes. The surgical removal of affected cancerous cells from the kidney provides a complete cure of the disease. A number of drugs are also available, which also help in the treatment of the disease when it is diagnosed at earlier stages.

Technavio's analysts forecast the global kidney cancer drugs market to grow at a CAGR of 7.36% over the period 2014-2019.

Covered in this Report

The report covers the present scenario and the growth prospects of the global kidney cancer drugs market for 2015-2019. To calculate the market size, the report considers the revenue generated from the sales of various approved therapies and off-label drugs used for the treatment of kidney cancer.The three regions covered in the report are as follows:

  • Americas: US, Canada, Mexico, and Brazil
  • EMEA: UK, Germany, Italy, France, and Spain and Middle Eastern and African countries such Israel, South Africa, Egypt, Sudan, Kuwait, Saudi Arabia, Qatar, and UAE
  • APAC: Japan, China, Australia, Singapore, South Korea, and India.
  • Technavio's report, Global Kidney Cancer Drugs Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.Key Regions
    • Americas
    • APAC
    • EMEA
    Key Vendors
    • Bayer
    • F. Hoffmann-La Roche
    • GlaxoSmithKline
    • Novartis
    • Pfizer
    Other Prominent Vendors
    • Abbott Laboratories
    • Active Biotech
    • Amgen
    • Argos Therapeutics
    • ArQule
    • AVEO Pharmaceuticals
    • Bionomics
    • Bristol-Myers Squibb
    • Cerulean Pharma
    • Exelixis
    • Genentech
    • immatics biotechnologies
    • Immunicum
    • Ono Pharmaceutical
    • Onyx Therapeutics
    • Oxford BioMedica
    • Prometheus Laboratories
    • Seattle Genetics
    • Taiwan Liposome
    • TRACON Pharmaceuticals
    • Wilex
    Market Driver
    • Increase in Patient Population
    • For a full, detailed list, view our report
    Market Challenge
    • High Cost of Drugs
    • For a full, detailed list, view our report
    Market Trend
    • Strategic Alliances
    • For a full, detailed list, view our report
    Key Questions Answered in this Report
    • What will the market size be in 2019 and what will the growth rate be?
    • What are the key market trends?
    • What is driving this market?
    • What are the challenges to market growth?
    • Who are the key vendors in this market space?
    • What are the market opportunities and threats faced by the key vendors?
    • What are the strengths and weaknesses of the key vendors?


    Press Release

    Technavio Announces the Publication of its Research Report – Global Kidney Cancer Drugs Market 2015-2019

    Technavio recognizes the following companies as the key players in the Global Kidney Cancer Drugs Market: Bayer, F. Hoffmann-La Roche, GlaxoSmithKline, Novartis and Pfizer

    Other Prominent Vendors in the market are: Abbott Laboratories, Active Biotech, Amgen, Argos Therapeutics, ArQule, AVEO Pharmaceuticals, Bionomics, Bristol-Myers Squibb, Cerulean Pharma, Exelixis, Genentech, immatics biotechnologies, Immunicum, Ono Pharmaceutical, Onyx Therapeutics, Oxford BioMedica, Prometheus Laboratories, Seattle Genetics, Taiwan Liposome, TRACON Pharmaceuticals and Wilex

    Commenting on the report, an analyst from Technavio’s team said: “Individuals tend to develop resistance to monotherapies over a period, resulting in the increased preference for combination therapies, which are safe and more effective in the treatment of kidney cancer. For instance, Avastin (bevacizumab) in combination with interferons slows the proliferation of the disease. Combination drugs are selected depending upon the health condition of the patient and the severity of the disease. Combinations of IL-2 with interferons were more effective than IL-2 or interferon alone. Many other combination therapies are currently under investigation. For example, TRACON Pharmaceuticals is engaged in the phase II development of TRC-105 in combination with Inlyta for the treatment of RCC.”

    According to the report, the prevalence of kidney cancer worldwide has increased in recent years. Changes in lifestyle, increased consumption of alcohol, excessive smoking, and a rise in obesity because of sedentary life routines lead to the growing incidence of the disease. Apart from these, the growing elderly population also results in a high incidence of the disease, as kidney cancer usually affects individuals aged 45 and above. In addition, the prevalence of the disease was higher in developed countries than in developing nations. These factors together account for a steady rise in the patient population opting for kidney cancer medication.

    Further, the report states that a limited number of approved drugs for the treatment of kidney cancer are present in the market.

    Companies Mentioned

    Bayer, F. Hoffmann-La Roche, GlaxoSmithKline, Novartis, Pfizer, Abbott Laboratories, Active Biotech, Amgen, Argos Therapeutics, ArQule, AVEO Pharmaceuticals, Bionomics, Bristol-Myers Squibb, Cerulean Pharma, Exelixis, Genentech, immatics biotechnologies, Immunicum, Ono Pharmaceutical, Onyx Therapeutics, Oxford BioMedica, Prometheus Laboratories, Seattle Genetics, Taiwan Liposome, TRACON Pharmaceuticals, Wilex

    • Executive Summary
    • List of Abbreviations
    • Scope of the Report
      • Market Overview
      • Product Offerings
    • Market Research Methodology
      • Market Research Process
      • Research Methodology
        • Table Market Research Methodology
    • Product Profiles
      • Nexavar
        • Avastin
        • Votrient
        • Afinitor/Votubia
        • Proleukin
        • Inlyta
        • Sutent
        • Torisel
    • Introduction
    • Disease Overview
      • Understanding the Disease
        • Types of Kidney Cancer
          • Table Types of Kidney Cancer
        • Benign Kidney Tumors
          • Table Types of Benign Kidney Tumor
      • Risk Factors
        • Lifestyle and Job-related Risk Factors
        • Genetic and Hereditary Risk Factors
        • Other Risk Factors
      • Etiology and Pathogenesis
        • Inherited Gene Mutations
        • Acquired Gene Mutations
      • Signs and Symptoms
      • Diagnosis
        • Medical History and Physical Exam
        • Lab Tests
        • Imaging Tests
        • Biopsy
      • Staging
        • TNM Staging System
      • Management
        • Surgery
        • Ablation and Other Local Therapies
        • Radiation Therapy
        • Targeted Therapy
        • Biologic Therapy (Immunotherapy)
        • Chemotherapy
      • Epidemiology
        • Table Prevalence of Kidney Cancer by Gender
      • Economic Burden
    • Pipeline Analysis
      • Table Global Kidney Cancer Drugs Market: Pipeline Portfolio
      • Key Information on Pipeline Candidates
        • AGS-003
        • Rencarex
        • Cometriq
        • IMA901
        • AV-951
        • TroVax
        • MPDL3280A
        • Opdivo
        • Naptumomab Estafenatox
        • Carfilzomib
    • Market Landscape
      • Market Overview
      • Market Size and Forecast
        • Table Global Kidney Cancer Drugs Market 2014-2019 ($ billions)
      • Five Forces Analysis
    • Market Segmentation by Molecule Type
      • Table Segmentation of Global Kidney Cancer Drugs Market by Molecule Type
      • Small Molecules
      • Biologics
    • Geographical Segmentation
      • Table Segmentation of Global Kidney Cancer Drugs Market by Geography 2014
    • Buying Criteria
    • Market Growth Drivers
      • Table Major Drivers in Global Kidney Cancer Drugs Market
    • Drivers and Their Impact
    • Market Challenges
      • Table Major Challenges in Global Kidney Cancer Drugs Market
    • Impact of Drivers and Challenges
    • Market Trends
      • Table Major Trends of Global Kidney Cancer Drugs Market
    • Trends and Their Impact
    • Vendor Landscape
      • Competitive Scenario
        • Key News
        • Mergers and Acquisitions
      • Market Share Analysis 2014
        • Bayer
          • Table Bayer: YoY Growth and Revenue of Nexavar 2010-2014 ($ millions)
        • F. Hoffmann-La Roche
          • Table F. Hoffmann-La Roche: YoY Growth and Revenue of Avastin 2010-2014 ($ millions)
        • GlaxoSmithKline
          • Table GlaxoSmithKline: YoY Growth and Revenue of Votrient 2010-2014 ($ millions)
          • Table GlaxoSmithKline: Revenue of Votrient by Region 2010-2014 ($ millions)
        • Novartis
          • Table Novartis: YoY Growth and Revenue of Afinitor 2010-2014 ($ millions)
          • Table Novartis: Revenue of Afinitor by Region 2012-2013 ($ millions)
          • Table Novartis: YoY Growth and Revenue of Proleukin 2012-2014 ($ millions)
        • Pfizer
          • Table Pfizer: YoY Growth and Revenue of Inlyta 2012-2014 ($ millions)
          • Table Pfizer: YoY Growth and Revenue of Sutent 2010-2014 ($ millions)
      • Other and Future Prominent Vendors
    • Global Kidney Cancer Drugs Market: Key Takeaways
      • Table Global Kidney Cancer Drugs Market: Key Takeaways
    • Key Vendor Analysis
      • Bayer
        • Key Facts
        • Business Overview
        • Business Segmentation by Revenue 2014
          • Table Bayer: Business Segmentation by Revenue 2014
        • Business Segmentation by Revenue 2013 and 2014
          • Table Bayer: Business Segmentation by Revenue 2013 and 2014 ($ billions)
        • Geographical Segmentation by Revenue 2014
          • Table Bayer: Geographical Segmentation by Revenue 2014
        • Business Strategy
        • Recent Developments
        • SWOT Analysis
      • F. Hoffmann-La Roche
        • Key Facts
        • Business Overview
        • Business Segmentation
          • Table Business Segmentation of F. Hoffmann-La Roche 2013
        • Business Segmentation by Revenue 2012 and 2013
          • Table F. Hoffmann-La Roche: Business Segmentation by Revenue 2012 and 2013
        • Sales by Geography
          • Table F. Hoffmann-La Roche: Sales by Geography 2013 (Pharmaceuticals Division)
          • Table F. Hoffmann-La Roche: Sales by Geography 2013 (Diagnostics Division)
        • Business Strategy
        • Key Information
        • SWOT Analysis
      • GlaxoSmithKline
        • Key Facts
        • Business Overview
        • Business Segmentation by Revenue 2014
          • Table GlaxoSmithKline: Business Segmentation by Revenue 2014
        • Business Segmentation by Revenue 2013 and 2014
          • Table GlaxoSmithKline: Business Segmentation by Revenue 2013 and 2014 ($ billions)
        • Geographical Segmentation by Revenue 2014
          • Table GlaxoSmithKline: Geographical Segmentation by Revenue 2014
        • Business Strategy
        • Recent Developments
        • SWOT Analysis
      • Novartis
        • Key Facts
        • Business Description
        • Business Segmentation
          • Table Novartis: Business Segmentation
        • Revenue by Business Segmentation
          • Table Novartis: Revenue by Business Segmentation 2013
        • Revenue Comparison 2012 and 2013
          • Table Novartis: Revenue by Business Segmentation 2012 and 2013 ($ millions)
        • Sales by Geography
          • Table Novartis: Revenue by Geographical Segmentation 2013
        • Business Strategy
        • Key Developments
        • SWOT Analysis
      • Pfizer
        • Key Facts
        • Business Overview
        • Business Segmentation by Revenue 2014
          • Table Pfizer: Business Segmentation by Revenue 2014
        • Business Segmentation by Revenue 2013 and 2014
          • Table Pfizer: Business Segmentation by Revenue 2013 and 2014 ($ billions)
        • Geographical Segmentation by Revenue 2014
          • Table Pfizer: Geographical Segmentation by Revenue 2014
        • Business Strategy
        • Key Developments
        • SWOT Analysis
    • Other Reports in This Series

    Download our eBook: How to Succeed Using Market Research

    Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

    Download eBook

    Share this report